Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
BEIJING, China, December 19, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that the US FDA has approved the Investigational New…
Read more
American Society for Cell Biology 2022
Join us at booth #704 at Cell Bio 2022 from December 3-7 in Washington, DC, hosted by American Society for Cell Biology (ASCB)! Whether you need…
Read more
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BEIJING, China, November 28, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option…
Read more
Antibody Engineering & Therapeutics 2022
Join us at booth #608 at Antibody Engineering & Therapeutics 2022 in San Diego, CA, December 4 - 8! Learn more about our antibody discovery…
Read more
First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients
Beijing, China and San Diego, CA, November 21, 2022 - Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing)…
Read more
BioMice’s Target Humanized Mouse Models Enable Preclinical Toxicity Studies to Support IND Approval
In February 2022, to meet the challenge of NHP shortage, the Food and Drug Administration (FDA) published a new guideline - Nonclinical Considerations for Mitigating…
Read more
Neuroscience 2022
Join us at booth #2703 at Neuroscience 2022 in San Diego, CA, November 12-16! Learn more about our latest model and service offerings. Whether you…
Read more
Biocytogen to Deliver 1 Oral and 3 Poster Presentations at PEGS EUROPE 2022, Introducing RenLite Platform, TCR-mimic Platform, and Antibody Assets
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that the company will present at the upcoming Protein & Antibody Engineering Summit (PEGS EUROPE)…
Read more
37th SITC Annual Meeting 2022
Join us at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA! Our booth will be open to greet visitors on…
Read more
Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022
Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022. The company will give an oral…
Read more